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Introduction
Tacrolimus (FK506) and cyclosporine (cyclosporin A, CsA) are cornerstone
immunosuppressive agents administered to solid organ transplant recipients to prevent and
treat allograft rejection. The discovery of cyclosporine in the 1970s, and its entry into the
collection of immunosuppressants in the early 1980s, was a major breakthrough in medicine.
Cyclosporine was the most successful antirejection drug to date, and it radically improved
the chance of survival for transplant recipients. In 1994, the Food and Drug Administration
(FDA) approved tacrolimus, an effective alternative to cyclosporine [1]. Since then,
tacrolimus and cyclosporine have become the principal immunosuppressive drugs for solid
organ transplantation. The United States Organ Procurement and Transplantation Network
and the Scientific Registry of Transplant Recipients showed that in 2011, 86% of the 16 055
patients who received a kidney transplant were prescribed tacrolimus upon discharge, and
2.4% were prescribed cyclosporine. One year after transplant, 84 and 4% of patients
received tacrolimus and cyclosporine therapy, respectively [2]. Global differences exist in
the usage of tacrolimus and cyclosporine: 2008 figures from the Australia and New Zealand
Dialysis and Transplant Registry show that 61% of the 391 Australian patients who received
a deceased kidney donor graft were prescribed tacrolimus, and 35% were prescribed
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cyclosporine. At 1-year post-transplant, these numbers changed to 55 and 33% for
tacrolimus and cyclosporine, respectively [3]. Both drugs are also prescribed for liver,
intestinal, lung, and heart transplant recipients [2], and can be used to manage severe
autoimmune conditions, such as atopic dermatitis [4,5] and rheumatoid arthritis [6,7].
Tacrolimus and cyclosporine differ in their chemical structure: cyclosporine is a cyclic
endecapeptide [8], whereas tacrolimus is a macrocyclic lactone [9]. However, they act in a
similar manner. Both are calcineurin inhibitors; their main mechanism of action involves
inhibition of this important phosphatase [1]. Tacrolimus exhibits similar effects to
cyclosporine, but at concentrations 100 times lower [10]. Despite these differences in
potency, tacrolimus and cyclosporine both show excellent survival rates for grafts across
many comparative studies (summarized in Maes and Vanrenterghem [11]). However,
several studies have shown that use of tacrolimus is associated with a lower allograft
rejection rate compared with cyclosporine [12-14].
The principal adverse effects associated with tacrolimus and cyclosporine treatment are
neurotoxicity, nephrotoxicity, hypertension, hyperglycemia, gastrointestinal disturbances,
infections, and malignancy [15]. Although the two drugs have similar side-effect profiles,
they may differ in the frequency of effects. For example, tacrolimus is more likely to cause
alopecia [16], tremors [17], and new-onset diabetes mellitus [12], whereas cyclosporine is
associated with hyperlipidemia [18], hypertrichosis, and gingival hyperplasia [19]. The idea
that tacrolimus is less nephrotoxic than cyclosporine remains controversial [20], particularly
as most studies of renal injury are based on evaluations in renal transplant patients, making
it difficult to discriminate between drug-induced organ damage and other causes of organ
dysfunction [21]. A recent study in pancreatic transplant recipients examined baseline
kidney biopsies and 5-year post-transplant biopsies, and reported that the chronic
nephrotoxic effects of tacrolimus and cyclosporine were similar [20].
Despite the success of both drugs, treatment is complicated by narrow therapeutic indices
and large intrapatient and interpatient pharmacokinetic variability [22,23]. Although
adequate exposure is essential to prevent rejection, overexposure can lead to toxicities that
reduce tolerability and affect long-term allograft and patient survival [24]. Therapeutic drug
monitoring (TDM), therefore, is mandatory for both drugs. However, because individual
transplant recipients respond differently to similar immunosuppressant concentrations,
achieving the recommended therapeutic target range does not guarantee absence of drug
toxicity or complete immunosuppressant efficacy. A mechanistic understanding of the
underlying factors affecting the pharmacokinetics and pharmacodynamics of calcinuerin
inhibitors may prove useful in being able to further personalize these therapies.
This review aims to provide a broad overview of recently published literature on the
pharmacokinetics, pharmacodynamics, and pharmacogenetics of tacrolimus and
cyclosporine in transplant patients, with the goals of clarifying current understanding and
identifying areas of future research. In doing so, this review builds on the work of others in
this field [1,8,24-27]. A particular emphasis is given to pharmacogenetics, as developments
in this area may provide a way to optimize treatment with these drugs, potentially avoiding
negative side effects while still maintaining efficacy.
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Pharmacokinetics
A schematic representation of tacrolimus and cyclosporine disposition within the body is
provided in Fig. 1. Tacrolimus and cyclosporine are usually administered orally [8,24], and
various formulations of the drugs are available for use. Both are Biopharmaceutics
Classification System (BCS) Class II drugs [28,29], indicating they are poorly soluble and
also highly lipophilic, and therefore readily absorbed through cell membranes [27,30].
Bioavailability of both drugs is generally poor with mean values around 25% [31,32].
However, it is important to note that wide variation in bioavailability is seen between
individuals using the two drugs [32,33]. Significant firstpass metabolism in the small
intestine and liver, as well as efflux from the intestine, both contribute to drugs’ low overall
bioavailability [34].
Upon entering enterocytes, both drugs are metabolized by gastrointestinal CYP3A isozymes,
predominantly CYP3A4 and CYP3A5 [35,36]. Studies have shown that CYP3A5 is the
predominant enzyme for metabolism of tacrolimus, with CYP3A4 contributing, but having a
lower efficiency for catalysis [37,38]. In contrast, cyclosporine is primarily metabolized by
CYP3A4 [39]. The CYP3A family of enzymes also includes CYP3A7 and CYP3A43 [40].
However, the involvement of CYP3A7 in cyclosporine metabolism is unclear [35], and it
has a low affinity and capacity toward tacrolimus, suggesting that it likely plays a minimal
role in tacrolimus metabolism [38]. Similarly, there is no evidence to support the
involvement of CYP3A43 in cyclosporine metabolism [35], and its role in tacrolimus
metabolism, if there is one, has yet to be elucidated [24]. Parent drug that escapes intestinal
metabolism enters the hepatic portal system and the liver, where CYP3A4 and CYP3A5
metabolize tacrolimus and cyclosporine [41,42]. Upon entering systemic circulation, both
drugs bind extensively to erythrocytes [1,43], and only unbound drug is capable of entering
lymphocytes and exerting its main immunosuppressive effects.
Up to 15 metabolites of tacrolimus may be formed [44], with the most prevalent being 13-O-
demethyl-tacrolimus [24,45]. This metabolite is approximately one-tenth as active as
tacrolimus, whereas a minor metabolite, 31-O-demethyl-tacrolimus, has been found to have
immunosuppressive activity comparable with tacrolimus [45,46]. The remaining metabolites
have weak or negligible pharmacological activity [46,47]. For cyclosporine, ~25 metabolites
are formed [48]. The major metabolites found in blood are AM1 and AM9, which are
hydroxylated products, and AM4N, which is N-demethylated [48]. CYP3A4 is capable of
transforming cyclosporine into AM1, AM9, and AM4N, whereas CYP3A5 only transforms
the drug into AM9 [39]. Reported immunosuppressive activity of these metabolites varies
between studies, but all metabolites studied so far have reduced activity compared with
cyclosporine [49,50]. AM1 has the highest immunosuppressive activity: one study reported
its activity to be close to 20% of native cyclosporine [50], whereas another found it to be as
high as 80% [49].
Both tacrolimus and cyclosporine are extensively metabolized, with less than 0.5 and 1%,
respectively, of the parent drug appearing unchanged in urine and feces [51,52].
Approximately 95% of tacrolimus metabolites are eliminated through the biliary route with
urinary excretion accounting for around 2% [51]. Similarly, cyclosporine metabolites are
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mainly excreted in the bile, with only around 3% of the drug undergoing renal elimination
[52,53].
In addition to CYP3A4 and CYP3A5, the efflux transporter P-glycoprotein also plays a
major role in the pharmacokinetics of tacrolimus and cyclosporine [34]. Encoded by the
ABCB1 gene, it pumps xenobiotics from the cytoplasm to the exterior of the cell [54]. It is
present on the apical surface of cells, and transports both tacrolimus and cyclosporine [55].
P-glycoprotein is present at high concentrations in the villus tip of enterocytes of the small
intestine [56,57] and lowers intracellular concentrations of both drugs by pumping them out
of enterocytes into the intestinal lumen [54]. Variation in intestinal P-glycoprotein was
found to account for ~ 17% of the variability in oral clearance of cyclosporine, where higher
levels of P-glycoprotein indicated higher observed clearance of the drug. Indeed, the same
study concluded that 75% of interpatient variability in cyclosporine clearance could be
explained by variation of both CYP3A4 activity in the liver, and expression of P-
glycoprotein in enterocytes [54]. For tacrolimus, a strong inverse correlation was seen
between the concentration/dose ratio of tacrolimus and the intestinal mRNA level of ABCB1
for the first 7 days after liver transplant in one study [58], and for the first 4 days after liver
transplant in another [59]. In addition to enterocytes, P-glycoprotein also transports drugs
across membranes within hepatocytes [60] and kidney cells [61,62]. It is also involved in
drug transport within lymphocytes [57,63], so the actual concentration of cyclosporine and
tacrolimus available for immunosuppression within these cells may be influenced by their P-
glycoprotein content. However, as P-glycoprotein’s role within enterocytes is better
characterized, Fig. 1 shows its involvement only in intestinal drug transport.
TDM of cyclosporine and tacrolimus is performed by adjusting drug dosage according to
concentrations within the blood. Evidence of an advantage for tacrolimus and cyclosporine
TDM over no monitoring has not been formally established in a randomized control trial.
However, given the narrow therapeutic indices of these agents, and their large
interindividual pharmacokinetic variability, it is widely accepted that TDM is beneficial
[64]. Although full dose interval area under the concentration–time curve from 0 to 12 h
(AUC0–12) is generally considered the best marker of overall drug exposure, the requirement
for collection of multiple samples over a 12-h period makes this approach infeasible within a
clinical setting, both financially and practically [64,65]. Subsequently, for reasons of
convenience, most transplant centers use trough blood concentration (C0) to guide
tacrolimus dosing [64], and C0 or 2-h postdose blood concentration (C2) to guide
cyclosporine dosing [66]. The strength of correlation between tacrolimus AUC and C0 is
still a matter of debate, with some studies finding better relationships between C3 [67], C4
[68], and C5 [69] and AUC. For cyclosporine, C0 monitoring was initially used, though C2
was later found to correlate better with cyclosporine AUC0–4, the time period in which
cyclosporine shows the greatest pharmacokinetic variability [66]. C2 was also shown to have
stronger associations with clinical outcomes compared with C0 [66]. However, limited
sample methods such as multiple linear regression or maximum a-posteriori (MAP)
Bayesian analyses may provide more accurate estimates of tacrolimus exposure than single
time points [65]. Large prospective trials are necessary to determine which of these
monitoring strategies is most expedient. Guideline targets for cyclosporine C2 levels have
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been suggested by the Consensus on Neoral C2: Expert Review in Transplantation
(CONCERT) committee [66]; target concentrations for liver and renal transplant patients
can be seen in Table 1. Targets for tacrolimus C0 in kidney, heart, and liver transplant
patients have also been proposed by a recent expert consensus document [64]. Information
from this report as well as from a separate report on lung transplant patients [70] can be
found in Table 1. Despite the consensus on target concentrations, the expert statement on
tacrolimus TDM noted the absence of multicenter, prospective, and concentration-controlled
trials that assess relationships between tacrolimus concentrations and clinical outcome, as
well as a lack of high quality studies that compare different TDM strategies to determine
which might be most advantageous [64]. In addition, a systematic review of cyclosporine C2
monitoring studies found that there was a lack of good quality studies comparing C0 and C2
monitoring, with the majority being observational or nonrandomized with highly
heterogeneous results. Furthermore, there is very limited evidence from prospective studies
that support the short-term clinical benefits of C2 monitoring, and the authors suggest that
better evidence from randomized and high quality trials is necessary to assess the advantages
of using C2 as a timepoint [72]. Although TDM is widely accepted as critical for patient
management, further studies are needed to clarify which clinically feasible time points give
the most accurate assessment of drug exposure.
Although rejection rates are low with modern immunosuppressive regimens, graft rejection
can still occur, even when whole blood tacrolimus and cyclosporine concentrations are
inside proposed therapeutic ranges [72]. It may therefore be more beneficial to monitor drug
levels at the site of action, either in the allograft tissue or within the lymphocyte itself, to
better predict drug efficacy. Several studies in liver transplant recipients have found that
hepatic tissue concentrations of cyclosporine [73] and tacrolimus [74,75] are significantly
lower in patients who experience rejection. Associations have also been seen between
variations in ABCB1 and intracellular peripheral blood mononuclear cell (PBMC)
concentrations of tacrolimus [76] and cyclosporine [77], as well as between intracellular
lymphocyte or PBMC concentrations and risk of acute rejection [75,78]; PBMCs represent a
blood compartment enriched with lymphocytes [75]. Further discussion of the relationship
between ABCB1 variants and lymphocyte intracellular concentrations can be found in the
Pharmacogenetics section. One study in 9 kidney transplant patients prescribed cyclosporine
found that intracellular T-lymphocyte AUC0–12 was 182% higher in the 5 patients who were
rejection free, compared with those patients who experienced rejection [78]. When
considering a larger group of 20 patients, the authors saw a significant decrease in T-
lymphocyte intracellular concentrations 3 days before the rejection episodes occurred in the
7 patients who experienced biopsy-proven acute rejection. In contrast, no significant results
were seen when considering any whole blood pharmacokinetic parameters, including dose,
C0 or C2 values [78]. As cyclosporine uses these parameters in TDM [66], this finding is
important in the context of drug monitoring. A study involving 90 liver transplant patients
taking tacrolimus found concordant results: patients who experienced clinical rejection had
intracellular tacrolimus trough concentrations that were 73, 77 and 76% lower on days 3, 5,
and 7 post-transplant, respectively, compared with patients with no or mild rejection. As
with cyclosporine, no association was seen between incidence of rejection and mean whole
blood C0 over days 5–7 [75]. This is important to consider, as tacrolimus TDM uses C0 to
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adjust dosage regimen [64]. Larger prospective trials are needed to further assess the clinical
relevance of using intracellular lymphocyte concentrations as part of TDM [78].
A number of drugs have been reported to interact with tacrolimus and cyclosporine.
Comprehensive lists can be found in reviews by Van Gelder [79], Christians et al. [80], and
Campana et al. [81]. Drug interactions mainly occur when tacrolimus or cyclosporine is
coadministered with either inhibitors or inducers of cytochrome P450 3A (CYP3A) or P-
glycoprotein [80], two proteins that have significant overlap in substrate specificities [82].
In addition to genetic polymorphisms, a large variety of nongenetic factors have reported to
influence the pharmacokinetics of tacrolimus and cyclosporine. These include transplant
population studied, time since transplant, drug formulation given, patient hepatic function
and liver allograft size, patient age, race and weight, patient hematocrit, albumin and
lipoprotein levels, circadian rhythm, coadministration with food, diarrhea, and concomitant
medications that induce or inhibit CYP3A or P-glycoprotein. Reviews by Staatz and Tett
[24] and Lindholm [83] provide a comprehensive discussion of factors associated with
variability in calcineurin inhibitor pharmacokinetics.
Pharmacodynamics
A stylized depiction of the mechanism of action of tacrolimus and cyclosporine in
lymphocytes as well as the candidate genes believed to interact with the two drugs is
provided in Fig. 2. Tacrolimus and cyclosporine exert immunosuppression by several
pathways, including inhibiting the calcineurin and the c-Jun N-terminal kinase (JNK) and
p38 pathways, and inducing the increased expression of transforming growth factor Ś1
(TGF-Ś1). The majority of studies on the pharmacodynamic effects of tacrolimus and
cyclosporine have focused on their effect within T cells. The involvement of natural killer
(NK) cells in transplant rejection is not very well defined, however, both drugs have been
found to inhibit natural killer cell degranulation in a dose-dependent manner [84].
Action on calcineurin and NFAT
Upon entering T cells, both cyclosporine and tacrolimus bind with high affinity to proteins
known as immunophilins. Cyclosporine binds mainly to cyclophilin A (encoded by the PPIA
gene), the predominant cyclophilin found within T cells, whereas tacrolimus binds to FK-
binding proteins, in particular FKBP12 (encoded by the FKBP1A gene). Both
immunophilins interact with calcineurin in the absence of any ligands. However, the affinity
of the immunophilin for calcineurin is enhanced upon binding of the drugs, resulting in the
inhibition of the protein’s activity [85]. Calcineurin is a calmodulindependent phosphatase,
which is stimulated during T cell activation by a chain of events involving calcium and
calmodulin [86,87]. Once activated, it associates with and dephosphorylates members of the
nuclear factor of activated Tcells (NFAT) family, thereby activating these proteins [88,89].
Upon activation, NFAT proteins translocate to the nucleus [89], where they associate with
other transcription factors, such as members of the activator protein-1 (AP-1) family, and
bind to DNA to promote the transcription of interleukin (IL)-2 [90]. They also bind to
promoter sites on a large variety of other cytokine genes, including those coding for IL-4,
IL- 10, and IL-17 [91]. Inhibition of calcineurin, therefore, prevents its ability to
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dephosphorylate and activate NFAT, affecting the transcription of cytokines important in the
immune response. The impact of the drugs on the transcription of IL-2 is probably the best
addressed mechanism, and this particular cytokine plays a major role in the immune
response, including the maintenance of regulatory T cells and the differentiation and
survival of CD4+ and CD8+ T cells [92].
In addition to NFAT and AP-1 family members, nuclear factor Ţ light-chain enhancer of
activated B cells (NF-ŢB) is also involved in the induction of IL-2 transcription [91,93,94].
NF-ŢB is the name given to a group of dimeric transcription factors that bind as homodimers
or heterodimers, and exert both positive and negative effects on gene transcription [95]. In
general, NF-ŢB has a large impact on the development, homeostasis, survival, and function
of Tcells [96]. It has a huge variety of target genes within T cells, and in addition to IL-2 is
also involved in the regulation of cytokines such as tumor necrosis factor-Ś[97] and
interferon-ś[98]. Calcineurin is also involved in the activation of NF-ŢB. It indirectly
induces the degradation of a compound known as IŢB, which is bound to inactive NF-ŢB
and acts as an inhibitory protein, preventing NF-ŢB from associating with its nuclear target
genes. The blockade of calcineurin activity by both drugs thereby affects the ability of NF-
ŢB to exert its action on the genes of the immune system [96,99].
Action on the JNK and p38 pathways
Though the effect of tacrolimus and cyclosporine on calcineurin is probably the best-studied
mechanism, both drugs are also thought to be involved in the inhibition of the mitogen-
activated protein kinase (MAPK) pathway. The MAPK pathway is a signaling cascade
involved in a wide variety of processes, particularly in cells within the immune system
[100]. It consists of three protein kinases: MAPK, MAPKK, and MAPKK-K. MAPKK-K
phosphorylates and activates MAPKK, which in turn phosphorylates and activates MAPK
[101]. There are three distinct MAPK subgroups – ERK, JNK, and p38 [100]. Both
cyclosporine and tacrolimus (in complex with their immunophilins) have been shown to
inhibit the JNK (MAPK8) and p38 (MAPK14) pathways, but not the ERK pathway. A study
in Jurkat T lymphocytes showed reduced levels of both the JNK and p38 proteins under the
administration of cyclosporine or tacrolimus [102]. JNK and p38 are activated through the
MAPK signaling cascade by T cell and CD28 costimulatory receptors [103], and upon
activation, translocate to the nucleus where they can fulfill their various roles [104]. This
includes regulating the activity of AP- 1 members [105], which are involved in promoting
the transcription of IL-2 [90] and other cytokines [106]. Indeed, the blockade of the p38 and
JNK pathways was shown to prevent the expression of the IL-2 gene [103]. The pathway of
JNK and p38 activation through various kinases can be seen in Fig. 2, and the two drugs are
thought to inhibit the pathways upstream of the MAPKKK level, as cyclosporine and
tacrolimus have both been shown to inhibit the activation of an MAPKK-K known as
MAP3K1 [102]. It is not believed that calcineurin is involved in this mechanism, as
inhibitors of calcineurin have been seen to block the activation of NFAT, but not JNK or
p38 pathways within T cells [102].
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Action on TGF-β1
TGF-Ś1 is a cytokine critical for the regulation of cells in the immune system. It is a member
of the TGF-Ś family, which also includes TGF-Ś2 and TGF-Ś3. TGF-Ś has been shown to
inhibit IL-2-dependent T cell proliferation [107], as well as exerting a variety of other
immunosuppressive effects within T cells [108]. In-vivo studies in patients with end-stage
renal disease undergoing transplantation have shown an increase in TGF-Ś1 protein and
mRNA expression after treatment with cyclosporine [109], and in-vitro studies of tacrolimus
in T cells also showed a significant increase in mRNA and protein levels after
administration of the drug [110]. However, the mechanism by which these drugs affect
levels of TGF-Ś1 remains to be elucidated. It is also important to note that some studies have
found evidence showing that neither tacrolimus nor cyclosporine are capable of affecting
TGF-Ś1 protein or mRNA levels at concentrations where IL-2 production is successfully
inhibited [111,112]. Therefore, at this stage, it is not possible to state definitively whether
the two drugs affect TGF-Ś1 levels at clinically relevant concentrations. However, it is
important to note that along with being involved in the immune system, TGF-Ś1 also has
fibrogenic properties that can lead to the development of nephrotoxicity [113]. A study in
renal transplant patients found that expression of TGF-Ś1 (TGFB1) mRNA within kidney
biopsies was increased in patients with either tacrolimus or cyclosporine nephrotoxicity,
compared with those who exhibited acute rejection. This suggests that increased levels of
the protein may lead to the nephrotoxicity often associated with these drugs [114].
Pharmacogenetics
A summary of genetic variants that show associations with tacrolimus or cyclosporine
pharmacogenetics, as well as their corresponding rsIDs and effects on the protein are shown
in Table 2. The majority of pharmacogenetic studies on tacrolimus and cyclosporine have
focused on the effects of variants in the CYP3A4, CYP3A5, and ABCB1 genes because of the
central role the enzymes and transporters they code for play in tacrolimus and cyclosporine
disposition. However, a few studies have examined the influence of single nucleotide
polymorphisms (SNPs) within the gene encoding the pregnane X receptor (NR1I2), which
regulates the expression of multiple genes including CYP3A and ABCB1 [127]. In addition, a
couple of studies have examined SNPs in the POR gene, which encodes for CYP450
oxidoreductase, a protein responsible for transferring electrons from NADPH to CYP450
enzymes, enabling their activity [128]. Finally, several studies have looked at variations in
the TGFB1 gene and their associations with renal dysfunction.
Within this section, we highlight only genes coding for metabolic enzymes or direct drug
targets. Two exceptions are the proteins encoded by cyclophilin A gene (PPIA), important in
that it allows cyclosporine to inhibit calcineurin, and CYP2C8, whose importance will be
explained further on. However, variations within cytokine genes also show associations with
side effects and outcomes. These include IL-6, where GG homozygotes at position − 174
had an increased risk of new-onset diabetes after transplantation [129], IL-12B, where the C
allele in rs3212227 conferred increased risk for cytomegalovirus infection with an odds ratio
(OR) of 1.52 [130], and IL-2, where TT homozygotes at position 330 had a higher risk of
developing chronic allograft nephropathy [131]. Patients in these studies were treated with
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either tacrolimus or cyclosporine as part of their immunosuppressive regime. However,
studies analyzing polymorphisms in cytokine genes and other innate immune response
molecules have been conflicted. For a review of these studies, please see Goldfarb-
Rumyantzev and Naiman [132].
Influence on tacrolimus pharmacokinetics and pharmacodynamics
An overview of tacrolimus pharmacogenetic studies can be found in Table 3. This table
provides information on the pharmacogenetic studies as they pertain to both
pharmacokinetic and pharmacodynamic parameters. A detailed discussion of tacrolimus
pharmacogenetics can be found below, segregated by gene.
CYP3A5 gene
Variations in the CYP3A5 gene have shown some of the firmest associations with tacrolimus
pharmacokinetics. In particular, the rs776746 SNP in intron 3 of the gene has been found to
be the strongest predictor of tacrolimus dosing requirements [133], and to explain up to 45%
of the variability in dose [154] and 30% of the variability in oral clearance of tacrolimus
[134]. Homozygosity for the G allele of this SNP (also referred to as CYP3A5*3) is
associated with a range of responses to tacrolimus, including increased dose-adjusted trough
concentrations (C0/D), decreased dose requirements, and decreased oral clearance [135,136].
The *3 allele affects CYP3A5 protein levels by creating a cryptic splice site within the
intron, resulting in altered mRNA splicing and eventually leading to a premature stop codon
and a nonfunctional protein. Patients homozygous for the *3 allele are known as CYP3A5
nonexpressers [115]. This reduction in enzymatic activity leads to the reduced dose
requirement – renal transplant patients who are CYP3A5 nonexpressers require lower mean
daily doses by ~ 0.05 mg/kg [135]. This association between CYP3A5 genotype and
tacrolimus metabolism has been replicated many times in a variety of different studies: a
recent systematic review of literature by the Royal Dutch Association for the Advancement
of Pharmacy found a very high level of evidence to support the gene–drug interaction.
However, they did not advise making dosing recommendations based on this genotype, as
tacrolimus dose is changed based on TDM [155].
As tacrolimus is metabolized by both intestinal and hepatic CYP3A5 enzymes, the
combined contribution of CYP3A5 expression in the native intestine and liver allograft is
likely to influence the pharmacokinetics of tacrolimus in liver transplant recipients [34].
Studies to date examining the relative influence of donor and recipient CYP3A5 rs776746
genotype in liver transplant patients have involved only small numbers of patients, and
hence have been somewhat inconclusive. Several studies have considered the combination
of donor and recipient CYP3A5 genotype on the C0/D of tacrolimus [156-158]. These
studies segregated patients into four groups based on whether they were a CYP3A5
expresser (CYP3A5*1/*1 or *1/*3) or nonexpresser (CYP3A5*3/*3): recipient expresser and
donor expresser (RE/DE), recipient expresser and donor nonexpresser (RE/DN), recipient
nonexpresser and donor expresser (RN/DE), or recipient nonexpresser and donor
nonexpresser (RN/DN). One study in 58 living Korean donors and liver transplant recipients
showed that, shortly after transplant, the tacrolimus C0/D ratio was significantly higher in
RN/DE group members than RE/DN group members. However, over time, the tacrolimus
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C0/D ratio in the RN/DE group decreased until, after 1 month post-transplant, the RN/DE and
RE/DN groups had similar C0/D values. The authors concluded that native intestinal
genotype had the most significant influence on tacrolimus metabolism in the early stages
after transplantation, but after enough time had passed for the transplanted liver to enlarge in
mass and regenerate from ischemia reperfusion injury, donor liver genotype became
increasingly important [156]. A second study involving 51 Japanese living liver donors and
recipients reported supporting results – patients with the RN/DN and RN/DE combination
genotypes displayed similar C0/D values at weeks 2–4 and months 2–6 after transplant.
However, at months 8, 10, and 12 posttransplant, values across the groups began to
significantly differ, with RN/DN patients showing a C0/D ratio 125% higher than that of
RN/DE patients. In contrast, differences between RN/DN and RE/DN genotype groups were
significant in the early post-transplant period, but only up to 6 months after transplant. These
two sets of results suggest that the donor expresser genotype has a greater influence on the
metabolism of tacrolimus, but only after 6 months. Before this time, the impact of recipient
genotype is more significant [157]. In contrast, Yu et al. [158], in their study involving 53
cadaveric transplant patients, reported that only RN/DN and RE/DE genotype groups
displayed significant differences in tacrolimus C0/D ratio, and only at 2 weeks and 1 month
post-transplant. Results at 1 week post-transplant were nonsignificant, and no other time
points were measured.
A number of studies have also examined the effect of donor and recipient genotype without
considering combinational influence. A study involving 50 Chinese cadaveric liver
recipients reported that donor CYP3A5 nonexpressers had significantly higher C0/D ratios at
2 weeks and 1 month post-transplant, as compared with expressers. However, no significant
difference was seen at 1 week. In contrast, recipient CYP3A5 genotype had no effect on
C0/D at any of the time points studied [159]. The previously mentioned study by Yu et al.
[158] also found the same results in their cohort of cadaveric liver transplant recipients,
when donor and recipient were considered separately. Two other studies in 60 living donor
[160] and 70 unspecified living or cadaveric donor [161] transplant patients, however, found
that donor genotype did significantly affect C0/D at 1 week, as well as weeks 2 and 3 for one
study [161], and months 1–12 for another study [160]. In addition, while the study in 60
patients found that recipient genotype was only significant at weeks 1 and 2 [160], the study
in 70 patients saw that recipient genotype had no effect on C0/D at any time [161].
Although it appears that donor genotype does play a significant role in tacrolimus
pharmacokinetics, it is unclear at what point it becomes relevant. Although several studies
show that donor genotype significantly alters C0/D values from the first week, others show
that it doesn’t begin playing a role until the second week or even the sixth month post-
transplant. In addition, evidence is conflicted for the role of the intestinal, or recipient,
genotype: a few studies show it is never significant, whereas others show it is significant
only up to the timepoint at which donor genotype becomes significant. Studies considering
donor genotype in liver transplant patients are not included in Table 3. This is because of
their limited number relative to those which included renal transplant patients, and the
complex combinatory effects of donor liver and recipient intestinal genotypes on
pharmacokinetic parameters.
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Though the Royal Dutch Association for the Advancement of Pharmacy does not
recommend adjusting dosing based on genotype [155], recipient or donor, a 2011
multicenter study on renal transplant patients found that dosing based on recipient
CYP3A5*3 genotype was beneficial: patients whose dosage was adapted based on genotype
had tacrolimus trough blood concentrations in the target range more frequently than those on
the standard regimen. In addition, patients on the genotypeadapted dosage required less time
to reach the target range and had a lower number of dose modifications. Nevertheless, the
improved dosing accuracy did not result in any positive clinical endpoints; there was no
difference in occurrences of acute rejection, nephrotoxicity or delayed graft function
between those on the adapted dose and those on the standard regimen. Therefore, it is still
uncertain whether taking tacrolimus pharmacogenetics into account when dosing would be
clinically relevant [162]. Indeed, there is a lack of consistent evidence for organ rejection as
a result of genotype-related under-immunosuppression, likely because careful tacrolimus
dose adjustments are performed in the early phase after transplantation in response to
measured trough concentrations [26]. However, several studies in renal transplant patients,
including one relatively large study with 304 participants, have shown an association
between the CYP3A5*3 allele and a decreased risk of nephrotoxicity [137,141,163]. One of
these studies, by Glowacki et al. [137], considered donor kidney genotype, but only found
significant results for nephrotoxicity when considering recipient genotype. The mechanism
behind this pharmacodynamic effect is unclear, but could stem from a lower systemic
exposure to the drug because of lower dose requirements [141], as well as potentially a
reduction in renal metabolite formation [163]. CYP3A5 is primarily responsible for
transforming tacrolimus into its metabolites, and in-vitro experiments have shown that
formation of the 13-Odemethyl- tacrolimus metabolite was 13.5-fold higher in human
kidney microsomes with the CYP3A5*1/*3 genotype, than those with the CYP3A5*3/*3
genotype [37]. It is possible that an increased amount of these metabolites in renal cells
could induce or aggravate nephrotoxicity [163]. Decreased levels of the fibrogenic TGF-Ś1
resulting from lower drug doses could also lead to a reduced incidence of nephrotoxicity. In
contrast, a smaller study in renal transplant patients found that CYP3A5*3 homozygotes
have an increased incidence of nephrotoxicity [137]. In addition, a study within liver
transplant patients also found that recipient CYP3A5 *3/*3 genotype was associated with an
increased risk of nephrotoxicity. No significant results were seen when considering donor
genotype. The authors suggested active CYP3A5 in the kidney may help reduce exposure of
renal cells to tacrolimus, thereby exerting a protective role [160]. Given these conflicting
results, at this time it is difficult to pinpoint any particular pharmacodynamic role for
CYP3A5.
Other CYP3A5 SNPs have also been found to affect tacrolimus pharmacokinetics, including
rs10264272 (CYP3A5*6) and rs41303343 (CYP3A5*7), which both lead to nonfunctional
proteins [116]. These are rare or absent in Asian or Caucasian populations, but are found
commonly in those of African descent. A study in Brazilian individuals (who tend to have a
significant amount of African ancestry) found that genotyping both of these alleles, along
with CYP3A5*3, is critical for determining the activity level of the CYP3A5 enzyme, and
therefore the appropriate dose of tacrolimus for those of African descent. Results showed
that as the number of defective alleles decreased from two to one to zero, the tacrolimus
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dose-adjusted trough concentration also decreased, which is consistent with the inferred
activity phenotype of these alleles. No such association was seen for cyclosporine [116], and
no associations have been seen between these SNPs and any pharmacodynamic parameters.
CYP3A4 gene
Within CYP3A4, rs2740574 (CYP3A4*1B), and rs35599367 (CYP3A4*22) have both shown
associations with tacrolimus dose requirements. rs2740574 is a promoter variant, and is
known to increase gene transcription [117]. Carriers of the *1B allele have been seen to have
35% lower tacrolimus dose-adjusted trough concentrations compared with those
homozygous for the normal *1 allele [164]. However, rs2740574 was shown to be in linkage
disequilibrium (LD) with rs776746 within the CYP3A5 gene, so its effect on tacrolimus
dosage requirements (as well as any pharmacodynamic parameters) is likely mediated by
this SNP [165]. A small number of haplotype studies looking at combinations of the
CYP3A4*1B and CYP3A5*3 alleles have found significant associations with tacrolimus
pharmacokinetics [163,166]. Though given the strong evidence supporting the role of
CYP3A5*3 in tacrolimus pharmacokinetics [155], and the LD between these two alleles
[165], any effect of this haplotype may be due to the CYP3A5*3 allele. rs35599367 is
present in intron 6 of the CYP3A4 gene, and results from a C to T substitution. *22 allele
carriers require a mean daily dose of tacrolimus 33% lower than wild-type homozygotes to
reach the same predose tacrolimus blood concentration [143]. *22 carriers also have reduced
mRNA and enzyme activity levels compared with wildtype homozygotes [119]. Unlike
CYP3A4*1B, rs35599367 is not in LD with rs776746, and it partially contributes to the
variation in tacrolimus dose requirement independently of the CYP3A5*3 allele [144].
CYP3A4*18 is another allele recently discovered to affect tacrolimus pharmacokinetics.
Also known as rs28371759, the SNP is found in intron 10 of the CYP3A4 gene, is
characterized by a G to A substitution, and is suggested to increase CYP3A4 activity [118].
Wild-type homozygotes for this allele had a reduced apparent clearance of tacrolimus
compared with carriers of the mutant allele [138]. However, like rs2740574, this allele is
also in LD with rs776746 [167]. There is very little evidence to support an influence of
CYP3A4 gene SNPs on pharmacodynamic outcomes relevant to tacrolimus – associations
between CYP3A4*1B have so far been exclusively negative [26]. To the best of our
knowledge, no association studies between the CYP3A4*18 or the *22 alleles, and the
pharmacodynamics of tacrolimus, have been completed at this time.
ABCB1 gene
Associations between tacrolimus pharmacokinetics and variations in ABCB1 have been
variable. A recent systematic review of available literature found no consistent evidence for
an association between tacrolimus doseadjusted trough concentrations and rs1045642
(3435C> T), a well-studied SNP within the gene [139]. rs1045642 had been of particular
interest, as it was shown to reduce intestinal P-glycoprotein expression and function, and
therefore had the potential to affect drug bioavailability [120]. Evidence supporting the
involvement of other ABCB1 SNPs in tacrolimus dose-adjusted exposure has also been
inconsistent. A large number of studies have also failed to find any association between
rs2032582 (2677G>T/A) and rs1128503 (1236C>T), two other commonly studied SNPs,
and tacrolimus pharmacokinetics [25]. However, one retrospective study of 81 renal
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transplant patients found that T allele homozygotes in both SNPs had higher dose-adjusted
trough concentrations compared with wild-type homozygotes 1 month after tacrolimus
introduction. T allele homozygotes for rs2032582 had 55% higher dose-adjusted trough
concentrations; T allele homozygotes for rs1128503 had 45% higher dose-adjusted trough
concentrations [168]. Another study in 83 lung transplant patients found that T allele carriers
for rs2032582 also had higher dose-adjusted trough concentrations as compared with GG
homozygotes, but only in the first month after transplant [169]. Haplotype analyses using
these three ABCB1 alleles have also been conducted: the same study of 81 renal transplant
patients found that those with the C-G-C haplotype for the SNPs rs1045642, rs2032582 and
rs1128503, respectively, required higher daily doses of tacrolimus compared with those with
the T-T-T haplotype [168]. Studies suggest that these three alleles are in LD to some extent
[61,170,171], hence it is uncertain whether only one of these three alleles is driving
associations with pharmacokinetic or pharmacodynamics parameters for tacrolimus or
cyclosporine. rs2032582 and rs1045642 in particular have shown strong LD, with r2 [170]
or D̘[61] values above 0.8. In addition, rs2032582 is a nonsynonymous SNP, whereas the
remaining two SNPs are synonymous, suggesting that it may be the main effector behind
any influence on the gene [171]. Indeed, a pharmacodynamic study, discussed later in this
paper, found that rs2032582 was the driving force behind an association of an ABCB1
haplotype with acute rejection in cyclosporine-treated patients [170]. Despite this, only
rs1045642 has been shown to affect ABCB1 expression [120]. A number of other studies
have found no relationship with ABCB1 haplotype combinations, including one with 206
renal recipients, in which haplotype associations were not significant after CYP3A5 status
was taken into account [172]. This suggests that, with or without LD, these alleles likely
play a minor role in affecting tacrolimus pharmacokinetics compared with the effect of
CYP3A5 alleles [172].
However, it is possible that ABCB1 alleles may play a stronger role in affecting intracellular
concentrations of tacrolimus within lymphocytes. A 2010 study by Capron et al. [76] in 96
renal transplant patients found that carriers of the rs1045642 Tallele had a 1.3-fold increase
in intracellular PBMC tacrolimus trough concentrations as compared with noncarriers. This
finding agrees with the assumed effect of the T allele, which is a reduction in P-glycoprotein
expression and function [120]. The authors also found that carriers of the ABCB1 rs2032582
T/A allele or the rs2229109 A allele showed significantly increased PBMC concentrations
compared with noncarriers, by 1.3- and 1.4-fold, respectively [76]. rs2229109 represents a G
to A change at position 1199 in the ABCB1 gene. It is not as well studied as rs1045642 or
rs2032582, and has varied and drug-specific effects on efflux [173-175]. In this case, as with
rs1045642 and rs2032582, it appears to reduce activity toward tacrolimus. It should be noted
that only rs1045642 and rs2229109 remained significantly associated with intracellular
concentrations once multivariate analyses were used; the initial association of rs2032582
was suggested to be because of its LD with rs1045642. None of these three alleles was
associated with tacrolimus blood concentrations, leading the authors to conclude that
ABCB1 polymorphisms may have a greater influence on intracellular concentrations than on
blood concentrations. Indeed, the authors also noted that intracellular PBMC concentrations
did not correlate significantly with blood concentrations, demonstrating that blood
concentration may not accurately reflect the level of tacrolimus capable of
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immunosuppression within lymphocytes. Unfortunately, though links have been shown
between intracellular concentrations and rejection, the authors could find no association
between these particular ABCB1 polymorphisms and rejection in the population. This may
be because of the low incidence of rejection episodes in the group, only 6% [76]. As
intracellular concentrations have been shown to be significant predictors of acute rejection,
understanding more about the role of ABCB1 variants in affecting lymphocyte
concentrations could potentially help reduce risk of allograft rejection in the future. This
study is not included within Table 3.
Though the study by Capron et al. [76] found no association between these three ABCB1
variants and rejection, the TT genotypes for SNPs rs1045642, rs2032582, and rs1128503
have all been associated with higher success rates in achieving short-term remission of
ulcerative colitis (UC) as compared with the other genotypes [145]. Along with drugs such
as infliximab, calcineurin inhibitors are also used to treat steroidrefractory UC [176]. A total
of 84 patients prescribed tacrolimus participated in this study, and the ORs for achieving
short-term remission with the TT genotype were 2.16, 1.59, and 1.74, respectively, for each
ABCB1 SNP. In addition, these effects were seen after correction for age, sex and tacrolimus
dose-adjusted trough levels, among several other nongenetic factors [145]. As rs1045642 is
thought to affect intestinal P-glycoprotein expression [120], it was suggested that the local
intestinal action of tacrolimus on UC might be why an association existed in this particular
study, but not in pharmacokinetic or clinical response studies in transplant patients [145].
Associations between ABCB1 alleles and other pharmacodynamic effects have been
inconsistent, and a large number of studies have failed to show any relationship between
rs1045642, rs2032582, and rs1128503 and pharmacodynamic parameters such as graft loss
or acute rejection (summarized in Staatz et al. [26]). Nevertheless, a few studies have found
associations between these SNPs and clinical outcomes. A study in 117 lung transplant
recipients found that rs1045642 TT homozygotes had a lower incidence of acute rejection by
25% [177]. In addition, a study with 120 liver recipients found that the rs2032582 Tallele
was associated with a lower risk of chronic renal dysfunction – TT homozygotes had an OR
of 0.26 when compared against all other genotype combinations for this SNP (i.e. GG, GT,
AG, AT) [178]. The T-G-C haplotype (in comparison with the wild-type C-G-C haplotype)
for the three main SNPs (respectively, rs1045642, rs2032582, and rs1128503) was found to
significantly increase the risk for chronic irreversible drug-induced nephrotoxicity (CNIT)
by an OR of 4.7 in 103 renal transplant patients. It was suggested that, as the presence of the
rs1045642 T allele reduces the efflux capacity of P-glycoprotein, it might lead to an
accumulation of the drug inside the cells [146]. This same haplotype combination was also
associated with a 1.4-fold increased risk for acute rejection, as compared with the wild type
or T-T-T variant haplotypes in a study of 832 renal transplant patients taking either
tacrolimus or cyclosporine [166]. This result is inconsistent with the previously mentioned
study, in which the Tallele from rs1045642 was associated with a lower rate of acute
rejection [177]. Results for neurotoxic associations also remain conflicted: wild-type
homozygotes for both rs2032582 and rs1128503 were found to have an increased risk for
neurotoxic events when taking tacrolimus, with an OR of ~ 3 in both cases [146]. However,
two other earlier studies found the opposite effect, in that the presence of the mutant T allele
in rs2032582 [179] or rs1128503 [180] was associated with a higher risk of neurotoxicity. It
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is important to note though, that within the neurotoxicity studies, the first study included 103
patients, whereas the latter two studies only included 17 and 63 patients, respectively. In
addition, each study differed in type of transplant patients, with patients undergoing renal,
liver, and hematopoetic stem cell transplants, respectively, making it hard to fairly compare
the results. Overall, however, studies relating ABCB1 alleles with tacrolimus
pharmacokinetics are generally inconsistent, and as there is a lack of mechanistic evidence
to back up any associations, it is difficult to ascertain which sets of results are valid.
POR and NR1I2 genes
Variants in POR and NR1I2 have also been found to affect tacrolimus pharmacokinetics. A
recent study in 158 adult kidney transplant patients showed that carriers of the 8055T allele
in the NR1I2 gene had a 33% higher doseadjusted exposure (AUC12/dose) to tacrolimus
compared with wild-type individuals [127]. NR1I2 is responsible for the upstream
regulation of drug-metabolizing enzymes and transporters, including the CYP3A family and
ABCB1. However, the mechanism behind the influence of the 8055T allele is still unclear
[127]. P450 oxidoreductase (POR) is responsible for enabling the activity of cytochrome
p450 enzymes [128]. Patients carrying at least one T allele of the rs1057868 SNP (also
known as POR*28) were found to have significantly lower tacrolimus trough concentrations
within the first few days after transplant, and require higher doses to maintain target
concentrations over the first year after surgery, as compared with wild-type homozygotes.
However, this effect was only seen in patients who were CYP3A5 expressers (i.e.
CYP3A5*1 allele carriers). It is thought that this SNP might modify the POR–cytochrome
interaction, affecting the activity of CYP enzymes [121]. Indeed, in-vivo studies with the
drug midazolam have shown that the *28/*28 genotype is associated with increased CYP3A
activity [181]. It is possible that the same effect may occur with tacrolimus, which would
lead to an increase in daily dose requirement for patients with that genotype [121]. Another
study showed supporting results, finding that patients heterozygous for the *28 allele had
35% lower levels of tacrolimus exposure (AUC24) compared with wild-type homozygotes.
This effect was also only significant in CYP3A5 expressers [147]. As of yet, no associations
have been found between variants in POR and pharmacodynamic effects. However, some
associations have been seen for the NR1I2 8055T variant. In the study of 158 adult renal
transplant patients (discussed above in regard to pharmacokinetic parameters), those in
possession of the T allele had a greater incidence of BK viremia during the first year of
treatment with tacrolimus compared with wild-type individuals, suggesting possible over-
immunosuppression. These T allele patients also carried a higher risk of BK viremia, with
an OR of 2.76, suggesting possible clinical relevance for the increase in dose-adjusted
exposure seen with this variant [127]. However, it is possible that the influence of the T
allele on BK viremia incidence occurred through a different mechanism than altered
immunosuppressant levels within the body, given that tacrolimus exposure in transplant
patients is controlled by TDM [127]. One possible mechanistic explanation is that, as NR1I2
regulates P-glycoprotein [182], it could alter the P-glycoprotein-mediated export of
tacrolimus out of lymphocytes [127].
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TGFB1 gene
Studies on TGFB1 have focused exclusively on renal side effects and outcomes. Patients
receiving tacrolimus and cyclosporine were combined in all but one of these studies
examined, so the discussion here will pertain to both tacrolimus and cyclosporine, and will
not be repeated in the cyclosporine section. The summary of tacrolimus pharmacogenetic
studies in Table 3 does not include data from the study with patients exclusively taking
cyclosporine [148]. The TGF-Ś1 protein is known to be associated with the development of
calcineurininhibitor nephrotoxicity [113], and is a potential target gene for tacrolimus and
cyclosporine [109,110]. All studies analyzing the relationship between renal dysfunction and
this gene have focused on two alleles: rs1800470 and rs1800471, and studies are
inconsistent about the effect of these alleles on clinical outcomes. CC homozygotes of the
former have increased serum levels of the protein [125], but the effect of the latter allele is
still unknown. Several studies, including one in 53 and another in 158 heart transplant
patients, have seen no associations between these alleles and renal dysfunction [151,152].
Another in 168 heart transplant patients taking only cyclosporine saw an association only for
rs1800470, where C allele carriers had a higher incidence of renal dysfunction [148]. The
largest study done so far in heart patients, with 237 members, saw concordant results: C
allele carriers for both variants had a higher risk of end-stage renal failure, with relative risks
of 2.9 and 2.6, respectively, for rs1800470 and rs1800471 [149]. However, a slightly smaller
study in 175 heart transplant patients found inconsistent results: CC homozygotes for
rs1800470 and C allele carriers for rs1800471, had improved progression of renal
insufficiency compared with the other genotypes [150]. Finally, one very large study with
4199 renal transplant patients found that neither TGFB1 variant was associated with graft
survival [153]. It is important to note that within this study peripheral blood lymphocytes
from the recipients were used for genotyping [153], therefore the negative result could be
explained by the fact that the donor genotype is more important than the recipient genotype.
However, this theory does not explain the discrepancies seen in the heart transplant patient
studies.
Other potentially important genes
Two other cytochrome p450 family members, CYP2C8 and CYP2J2, have also been
analyzed for relationships with tacrolimus-related clinical outcomes. Alleles in CYP2J2 have
not been associated with any pharmacodynamic factors to date [122,146]. However, the
CYP2C8*3 allele was associated with a higher risk of kidney dysfunction post-
transplantation, with an OR of almost 2.5 for those carrying at least one *3 allele. Patients in
this study had been treated with tacrolimus for at least 3 years, and this relationship was not
seen for cyclosporine [122]. A later study in renal transplant patients receiving tacrolimus
found that *3 homozygotes also had a higher incidence of delayed graft function compared
with *1 allele carriers. No relationship was seen between these alleles and acute rejection or
neurotoxicity [146]. Both of these enzymes are involved in the metabolism of arachidonic
acids (AAs) into epoxyeicosatrienoic acids (EETs), metabolites implicated in preventing
hypertension and maintaining normal renal function. Calcineurin inhibitors are believed to
influence the production of these AAs, indicating the potential importance of
pharmacogenetic studies on this gene. In-vitro studies showed that the enzyme products
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from the CYP2C8*3 genes were deficient in the epoxidation of AAs into EETs [122]. This
reduced transformation would lead to lower amounts of the protective EETs, which might
explain the higher incidence of delayed graft function and kidney dysfunction in the *3
carriers [146].
Influence on cyclosporine pharmacokinetics and pharmacodynamics
An overview of cyclosporine pharmacogenetic studies can be found in Table 4. This table
provides information on pharmacogenetic studies as they pertain to both pharmacokinetic
and pharmacodynamic parameters. A detailed discussion of cyclosporine pharmacogenetics
can be found below, segregated into pharmacokinetic and pharmacodynamic sections.
CYP3A5, CYP3A4, ABCB1, and pharmacokinetics
The impact of variants within CYP3A5, CYP3A4, and ABCB1 on cyclosporine
pharmacokinetics is controversial [25,186]. Studies have shown highly mixed results in
finding an association between the CYP3A5*3 and cyclosporine pharmacokinetics. Large
studies, such as one in 171 renal transplant patients [186] and another in 151 heart and renal
patients [193], have found no associations between this allele and cyclosporine
pharmacokinetics. However, a study in 110 renal recipients found that CYP3A5*3
homozygotes have higher dose-adjusted trough concentrations than heterozygotes [164], and
another a study in 91 bone marrow recipients reported that *3 homozygotes had greater
dose-adjusted trough concentrations on days 1–10 of treatment, and greater dose
requirements on days 16–30, as compared with *1 homozygotes [183]. This type of
inconsistency is common, and does not appear to be influenced by race. Indeed, three
different studies, all with around 100 Chinese renal recipients, found that, respectively, the
*3 allele was associated with higher dose-adjusted trough concentrations, lower dose-
adjusted trough concentrations, and not associated with trough concentrations at all
[194-196], exemplifying the type of conflicting evidence seen in these pharmacokinetic
studies. Indeed, the study finding lower dose-adjusted trough concentrations [196] is
particularly confusing, as the CYP3A5*3 allele results in a nonfunctional protein [115],
implying that dose-adjusted trough concentrations should be higher in *3 allele carriers.
Similar to tacrolimus, the influence of SNPs rs1045642, rs2032582, and rs1128503 within
ABCB1 are also unclear, and the majority of studies show no significant associations with
pharmacokinetic parameters [25]. Indeed, a meta-analysis of 1036 individuals showed no
influence of the rs1045642 SNP on any cyclosporine pharmacokinetic parameters except
increased AUC12 for T allele carriers [197]. A study in 106 renal transplant patients found
that the rs1128503 T allele was associated with increased dose-adjusted maximum blood
concentrations [198], but most of the other studies on rs1128503, as well as rs2032582, have
found no relationships [25]. Most studies, including one with 407 renal transplant patients
[166], also do not find any significant associations between ABCB1 haplotypes and
cyclosporine pharmacokinetics. Given this large number of negative results, it is probable
that SNPs within ABCB1 explain only a small amount of the variation in cyclosporine
pharmacokinetics, if any.
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However, as with tacrolimus and ABCB1 SNPs, a stronger association may be seen when
intracellular, as opposed to whole blood, concentrations of cyclosporine are considered. A
study by Crettol et al. [77] in 64 renal, liver, and lung transplant patients found that carriers
of the rs1045642 Tallele had 1.7-fold higher intracellular PBMC cyclosporine trough
concentrations compared with noncarriers. These results are in concordance with the study
by Capron et al. [76], who found a 1.3-fold increase in intracellular PBMC tacrolimus
concentrations for carriers of the T allele. However, unlike the study in tacrolimus, Crettol et
al. [77] found that the T allele was also associated with trough blood concentrations, with a
1.2- fold increase for carriers compared with noncarriers. No significant results were seen
for rs2032582 or rs1128503, the other two commonly studied ABCB1 SNPs [77]. Capron et
al. [76] did not study rs1128503, but found that rs2032582 was not significant in
multivariate analyses. However, results were different when considering the rs2229109 A
allele: while Crettol et al. [77] saw no association when considering blood concentrations,
which was the same result seen by Capron et al. [76] the authors also found that carriers of
this allele had 1.8-fold decreased intracellular concentrations compared with noncarriers.
This suggests that the A allele results in increased P-glycoprotein activity toward
cyclosporine, thereby reducing intracellular concentrations compared with noncarriers [77].
Capron et al. [76], in contrast, found a 1.4-fold increase in PBMC concentrations for A
allele carriers. Capron et al. [76] suggested that this difference was due the structural
dissimilarities between the two drugs, which may affect the way they interact with the P-
glycoprotein binding site. As rs2229109 is situated close to the domain involved in substrate
binding, changes in this SNP could affect binding affinities for tacrolimus and cyclosporine
differently. All patients that participated in the study by Crettol et al. [77] were stable, and
as no evidence of rejection was reported, no links between ABCB1 variants and rejection
were established. Similarly to Capron et al. [76] the authors reported that cyclosporine blood
concentrations correlated only moderately with intracellular concentrations (r2=0.30) [77],
again showing the potential importance of considering intracellular lymphocyte
concentrations in addition to blood concentrations. The study by Crettol et al. [77] is not
included within Table 4.
As CYP3A4 is the predominant enzyme involved in metabolizing cyclosporine [39], it
would be expected to show strong associations with cyclosporine pharmacokinetics,
particularly in comparison with CYP3A5. Despite this, evidence for an association between
CYP3A4*1B alleles and cyclosporine pharmacokinetics has been inconsistent, with several
studies showing no significant relationships [164,186,199,200]. Studies that have seen
associations include one with 151 heart and renal transplant patients [193], which reported
an increased clearance for *1B allele carriers, and one in 100 renal recipients, which showed
an increased mean dose requirement for *1B/*1 patients as compared with *1 homozygotes
by ~ 200mg/day [184]. These results are both consistent with the theory that the *1B allele
may increase gene transcription [117]. A very limited amount of work has been done
analyzing the relationship between CYP3A5*3 and CYP3A4*1B haplotypes and
cyclosporine pharmacokinetics, and only nonsignificant results have been seen [25]. Though
studies of the CYP3A4*1B allele have had conflicting results, several studies have recently
reported associations between the CYP3A4*18 allele and cyclosporine pharmacokinetics.
Patients homozygous for the wild-type *1 allele had 40% higher dose-adjusted trough
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concentrations (C0/dose) of cyclosporine on days 16–30 of treatment compared with *18
homozygotes. For 2-h postdose-adjusted concentrations (C2/ dose), the wild-type
homozygotes had concentrations 35% higher on days 16–30, and 19% higher on days 8–15
[167]. A different study found supporting results: *18 homozygotes had a 50% reduction in
2-h postdose concentrations compared with the other genotypes [189]. These concordant
results suggest that, indeed, the *18 allele may increase enzymatic activity, thereby reducing
levels of the drug in the body [189]. However, it is important to note that a strong LD (D̘
=0.88) between this allele and the CYP3A5*3 allele was observed [167]. Associations have
also been seen between rs35599367 (CYP3A4*22) and cyclosporine pharmacokinetics – *22
carriers had dose-adjusted trough concentrations 1.6-fold higher than *1/*1 homozygotes
[144], a result that is consistent with the finding that *22 carriers have reduced mRNA levels
and enzyme activity [119].
CYP3A5, CYP3A4, ABCB1, and cyclosporine pharmacodynamics
Studies analyzing the association between CYP3A5*3, CYP3A4*1B, and ABCB1 alleles and
cyclosporine pharmacodynamics have shown mixed results. Only one study, albeit
exceptional in its relative size (399 German renal recipients), found a significant association
between the CYP3A5*3/*3 genotype and a pharmacodynamic parameter: decreased patient
survival compared with *1 allele carriers [185]. The remaining studies have all seen
negative results [26,186].
A very limited number of studies have analyzed the effect of the CYP3A4*1B alleles on
pharmacodynamic parameters, and no relationships have been found at this point [26,186].
In addition, only one study has analyzed the combined haplotypic influence of CYP3A4*1B
with ABCB1 rs1045642, and saw no significant results [199]. No studies have looked at the
combined haplotype influence of CYP3A4*1B and CYP3A5*3 alleles on cyclosporine
pharmacodynamics. A recent study on the effect of rs35599367 (CYP3A4*22) on renal
transplant patients found that the *22 allele was associated with a higher risk of delayed
graft function compared with *1 homozygotes. Indeed, the OR was 6.3 after adjustment for
other factors such as age, sex or primary kidney disease [190].
A relatively large study that included 237 renal transplant patients found that the rs2032582
TT genotype in ABCB1 was associated with a three-fold higher risk of biopsy-proven acute
rejection compared with the other genotypes [170]. This SNP was found to be in high LD
with rs1045642 and rs1128503, and these two SNPs also showed association with acute
rejection, but only before adjustment for the rs2032582 SNP [170]. In addition, the same
authors found that the T-T-T haplotype for these SNPs (rs1045642, rs2032582, and
rs1128503, respectively) was associated with a two-fold increased risk for rejection
compared with the wild-type C-G-C haplotype [170]. Confusingly, the study in 832 renal
transplant patients treated with tacrolimus or cyclosporine found that the T-T-T haplotype is
associated with a lower risk of acute rejection, except in this case it was compared against
the T-G-C haplotype [166]. A different study in 68 renal transplant recipients also found an
association between the TT genotype and an increased risk of nephrotoxicity [191]. Various
other smaller studies have found no association between ABCB1 variants and clinical
outcomes (summarized in Staatz et al. [26]).
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However, several studies have shown the importance of considering donor ABCB1 genotype
when considering pharmacodynamic outcomes such as nephrotoxicity or rejection within
renal transplant patients. The study of ABCB1 variants in particular is important as P-
glycoprotein is highly expressed in renal proximal tubule epithelial cells, so activity in the
donor kidney could affect the development of cyclosporine-related adverse events [201].
Although variations in CYP3A5 or CYP3A4 genotypes in donor kidneys could also
conceivably affect levels of cyclosporine within renal cells, neither CYP3A5*3 or
CYP3A4*1B variants have shown significant associations with graft loss [187,201], or any
other adverse events of which we are aware at this time. However, a study of 97 renal
transplant donors and recipients of White ethnicity found that donor ABCB1 rs1045642 TT
genotype was highly predictive of nephrotoxicity – 40% of patients with this donor genotype
developed cyclosporine nephrotoxicity within two and a half years post-transplant,
compared with only 10% of those with the CT or CC donor genotypes. In multivariate
analysis, the TT genotype gave an OR of 13.4 for development of nephrotoxicity. No
significant association was seen for the rs2032582 SNP and nephrotoxicity [188]. Another
study in 259 renal transplant patients of unspecified ethnicity found similar results – the
homozygotes for the ABCB1 T-T-T haplotype (rs1045642, rs2032582, and rs1128503) had a
hazard ratio of 9.4 for development of graft loss, as compared with all other haplotype
combinations for these SNPs. Each TT genotype for rs1045642, rs2032582, rs1128503 was
also associated with graft loss as compared with the wild-type homozygotes, but in
multivariate analysis, only rs2032582 remained significant; patients with the TT genotype
had a hazard ratio of 12.1 for graft loss, as compared with the wild-type homozygotes [201].
These two findings further exemplify the conflict as to whether rs1045642 or rs2032582 is
driving associations between ABCB1 and various drug-related pharmacokinetic and
pharmacodynamic parameters. Despite these two sets of strong, albeit somewhat conflicted,
results, a recent study by Moore et al. [187] using a larger number of patients (670 in the
discovery cohort, 675 in a validation cohort) found entirely opposing results: patients with a
donor kidney rs1045642 CC genotype had an increased risk of long-term graft failure, as
compared against the CT or TT genotypes, with a hazard ratio of 1.7. One hundred percent
of patients were given cyclosporine in the discovery cohort, whereas 82.5% were given
cyclosporine in the validation cohort (the remaining were given tacrolimus). They were also
uniformly of White ethnicity. Another validation cohort in 2985 patients found no
significant association with donor genotype, which Moore et al. [187] suggested may be due
to the heterogeneity of the population – though patients were again all of White background,
they came from the Collaborative Transplant Study population, which includes participants
from multiple countries and transplant centers, in contrast to the single-center populations
used for the discovery and first replication cohort. These varied countries and centers may
all use different treatment approaches and algorithms, which could affect the data analysis.
No significant association was seen between the other two commonly studied SNPs,
rs2032582 or rs1128503. Moore et al. [187] suggested that the conflicting results seen with
previous studies of adverse outcomes could be because of population size or patient
characteristics, as well as the endpoints evaluated. The authors also evaluated donor and
recipient genotypes for CYP3A4, CYP3A5, NR1I2, and PPIA in the discovery cohort only,
but found no significant associations with allograft survival. Neither this study by Moore
and colleagues nor the study with 97 patients saw significant associations with recipient
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genotypes [187,188]; the study with 259 patients did not analyze recipient genotype [201].
Though significant results have been seen when considering ABCB1 donor genotype, studies
in this area are currently limited and highly conflicted. Information on donor genotype
results for these three studies is not included in Table 4. However, given that a number of
studies have analyzed pharmacodynamic outcomes in kidney transplant patients and
considered only recipient genotype [126,153,186,190,191] information on recipient
genotype from these donor-focused studies is included in Table 4. Very limited research has
been done investigating whether patients on tacrolimus therapy show the same relationship
between donor kidney genotype and renalrelated adverse events: one study showed that
combined donor and recipient ABCB1 rs1045642 TT genotypes was associated with an
increased risk of chronic allograft damage, with an OR of 3.9 when compared against all
other genotypes. The authors suggested that this could be caused by an accumulation of
tacrolimus within renal cells because of reduced function of this particular form of P-
glycoprotein. Recipient and donor rs1045642 TT genotypes were also associated with
chronic allograft damage individually, but only in univariate analyses. No association was
seen between ABCB1 genotypes and delayed graft function or graft survival [202].
It is possible that nongenetic factors play a larger role in determining patient response to
cyclosporine than do genetic ones. A recent genetic epidemiology study estimated the
heritability of induced CYP3A4 activity at 66%, implying that genetic factors do play a
large role, but environmental factors such as smoking and BMI may also significantly
influence enzymatic activity [203]. Indeed, a different study found that patient weight
explained 35% of the variability in cyclosporine oral clearance, and concomitant use of
prednisolone at doses 20 mg/day or higher was also associated with higher clearance of the
drug. However, no genotype effects of clinical relevance were seen, including SNPs in the
CYP3A4, CYP3A5, and ABCB1 genes, as well as NR1I2 [204].
Other potentially important genes
CYP3A7, another member of the CYP3A family along with CYP3A4 and CYP3A5, has
also shown some associations with cyclosporine pharmacokinetics. However, no association
with tacrolimus pharmacokinetics has been seen, likely because the enzyme has a low
affinity and capacity for the drug [38]. Carriers of the CYP3A7*1C allele required 1.4- to
1.6-fold higher cyclosporine daily doses than noncarriers during the first year after
transplantation [35]. Initially, it was believed that CYP3A7 was expressed exclusively in
fetuses, but later studies showed that it is expressed at significant levels within some adult
livers [205]. This allele was also demonstrated to be a marker of increased CYP3A7 mRNA
expression in both the adult liver [123,124] and the intestine [124], which supports the data
showing that carriers of the *1C allele require higher cyclosporine doses. However, its
mechanistic involvement in cyclosporine metabolism is still unknown [35].
Theoretically, polymorphisms in FK-binding protein, cyclophilin A and calcineurin genes
may affect the immunosuppressive potential of cyclosporine and tacrolimus. However,
limited studies have been done in this area. One study found that a promoter variant,
rs8177826 (– 11 C>G) in the cyclophilin A gene (PPIA), affected gene expression and
nephrotoxicity. Indeed, in the group of 290 kidney transplant patients taking cyclosporine,
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the strongest predictors of nephrotoxicity were a renal donor age of above 55 years, and GG
or GC genotypes in the promoter polymorphism. The C allele was associated with lower
gene expression, implying that the effect on nephrotoxicity could be mediated by higher
cyclophilin A expression in G allele carriers. No association with cyclosporine
pharmacokinetics was seen [126]. However, Moore et al. [187], as part of their study on the
effect of kidney donor genotype on development of allograft failure, analyzed several SNPs
within PPIA, including rs8177826, and found no associations with graft failure when
considering donor or recipient PPIA genotype. The study population consisted of 670 kidney
transplant patients prescribed cyclosporine.
Conclusion
Both tacrolimus and cyclosporine are invaluable drugs for the prevention of transplant
rejection. However, a great deal of their pharmacokinetic and pharmacodynamic variability
remains to be explained. Though the CYP3A5*3 allele has shown strong associations with
tacrolimus pharmacokinetics, very little consistent evidence has emerged for factors
affecting tacrolimus pharmacodynamics or cyclosporine pharmacokinetics and
pharmacodynamics. The overall inconsistency of these studies may be related to ethnic
variability, small numbers of patients, nonspecific pharmacokinetic assays, variation in
when outcomes are measured, and the impact of donor genotype – particularly in
nephrotoxicity studies in kidney transplant patients or pharmacokinetic studies in liver
transplant patients. Larger studies and metaanalyses that take ethnicity and donor genotype
into account may help resolve some of this variability. The vast majority of studies have
focused on single SNPs, and the potential role of haplotypes, both within and between
multiple genes, needs investigation. It is possible that combinations of SNPs have
synergistic effects on tacrolimus and cyclosporine pharmacokinetics or pharmacodynamics.
In addition, the exact and comprehensive mechanisms of the drugs’ immunosuppressive
actions are still being discovered. In particular, the contribution of altered expression of P-
glycoprotein within lymphocytes to the immunosuppressive effects of the drugs is unclear.
Further study of the pharmacokinetic, dynamic, and genetic aspects of these drugs should
help clinicians avoid the severe side effects associated with both of these drugs. Genotyping
before treatment for these drugs has potential for preventing side effects such as
nephrotoxicity, rejection, or neurotoxicity. However, currently no genes (or variations
within these genes) show consistent associations with pharmacodynamic parameters. Indeed,
only CYP3A5*3 shows reliably positive associations with pharmacokinetic parameters for
tacrolimus. As both tacrolimus and cyclosporine are subjected to careful dose-monitoring,
genotyping CYP3A5 to accurately predict dosage may not be necessary. Indeed, Thervet et
al. [162] found that, though patients given genotype-adapted tacrolimus dosing had trough
blood concentrations in the target range more often than those on the standard regimen, this
did not result in any positive clinical endpoints such as decreased incidence of rejection or
nephrotoxicity. To make genetic testing relevant for these drugs, further large-scale studies
should focus on whether testing for CYP3A5 nonexpressers before treatment with
tacrolimus improves clinical outcome. Further investigation should also be conducted on
genes such as TGFB1 and PPIA, which are potential or known gene targets of either
tacrolimus or cyclosporine. Variations in these genes could have a large impact on the
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development of side effects, but there is currently not enough research to make any strong
conclusions about their involvement. The effect of upstream CYP3A regulators such as POR
and NR1I2 should also undergo further research. The pharmacogenetics of tacrolimus and
cyclosporine is complex, and a great number of factors likely contribute to its variability.
However, improving our understanding in this area will have a significant impact on the
health and well-being of patients treated with these drugs.
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Fig. 1.
Schematic representation of tacrolimus and cyclosporine metabolism. A fully interactive
version is available at: http://www.pharmgkb.org/pathway/PA165986114.
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Fig. 2.
Stylized depiction of the mechanism of action of tacrolimus and cyclosporine in
lymphocytes, as well as the candidate genes believed to interact with the two drugs. A fully
interactive version is available at: http://www.pharmgkb.org/pathway/PA165985892.
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Table 1
Summary of suggested therapeutic target ranges for cyclosporine and tacrolimus
Organ
Cyclosporine (Neoral)a Tacrolimusb
Months post-transplant C2 target (µg/ml) Months post-transplant C0 target (ng/ml)
Kidney 2 1.5 0–3 10–15c
3 1.3 3–12 5–15c
4–6 1.1 > 12 5–10c
7–12 0.9 – –
12 + 0.8 – –
Liver 0–6 1.0 0–1 10–20
6–12 0.8 1–3 5–15
> 12 0.6 > 3 5–10
Heart – – 0–2 15–20
– – 2–6 10–15
– – > 6 8–10
– – > 6–9 (stable patients) 5–10
Lung – – 0–2 weeks 10–25
– – 6–10 weeks 10–20
– – > 10 weeks 10–15
Targets are separated by months post-transplant and type of organ. Only information for adult patients is included.
aData taken from Levy et al. [66].
bData for kidney, liver, and heart taken from Wallemacq et al. [64]; data for lung taken from Garrity et al. [70].
cTarget concentrations for renal transplant patients taking tacrolimus without induction therapy. Target values for patients taking tacrolimus with
IL-2 receptor antibody therapy, induction with thymoglobulin or with an mTOR inhibitor will vary. Please refer to Wallemacq et al. [64] or Schiff
et al. [71] for more information.
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Table 2
Summary of genetic variants that show associations with tacrolimus or cyclosporine pharmacogenetics
Gene name Variant rsID Effect on gene or protein References
CYP3A5 CYP3A5*3 rs776746 Nonfunctional protein Kuehl et al. [115]
CYP3A5*6 rs10264272 Nonfunctional protein Santoro et al. [116]
CYP3A5*7 rs41303343 Nonfunctional protein Santoro et al. [116]
CYP3A4 CYP3A4*1Ba rs2740574 Increase gene transcription Amirimani et al. [117]
CYP3A4*18b rs28371759 May increase enzyme activity Fukushima-Uesaka et al. [118]
CYP3A4*22 rs35599367 Reduced mRNA levels, reduced enzyme activity Wang et al. [119]
ABCB1 3435C > T rs1045642 Reduced protein expression and function Hoffmeyer et al. [120]
2677G > T/A rs2032582 Currently unknown
1236C > T rs1128503 Currently unknown
NR1I2 8055C > T rs2276707 Currently unknown
POR POR*28 rs1057868 May modify the POR-cytochrome interaction De Jonge et al. [121]
CYP2C8 CYP2C8*3 rs11572080 Reduced enzyme activity Smith et al. [122]
CYP3A7 CYP3A7*1C Increased mRNA expression Sim and colleagues [123,124]
TGFB1 29 T > C rs1800470 Increased serum concentration of protein Yokota et al. [125]
74 G > C rs1800471 Currently unknown
PPIA (cyclophilin A) – 11C > G rs8177826 Increased gene expression Moscoso-Solorzano et al. [126]
rsIDs (if known) and effects on the gene or protein are also listed. References pertain to the effect on the gene or protein.
a,bIn linkage disequilibrium with CYP3A5*3.
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